Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy

Fig. 1

Pattern of PSA and WBC values following sipuleucel-T treatment. Solid arrows: initial APC8015-2 (investigational form of sipuleucel-T produced using 2 μg/mL of PA2024) in December 2010 and subsequent treatment with commercial sipuleucel-T (using 10 μg/mL of PA2024) in December 2012. Open arrows: other therapies. Solid line: PSA prostate-specific antigen; Dotted line: WBC white blood cell count

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us